Axsome Therapeutics shares rise 1.08% intraday as RBC Capital Markets maintains its stance on the biopharma company.

Axsome Therapeutics, Inc. rose 1.08% in intraday trading, with RBC Capital Markets maintaining its stance on the biopharma company. Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and providing therapies for central nervous system (CNS) disorders with limited treatment options. The company's commercial products and development programs include Auvelity and Sunosi, which are used for treating severe depressive disorders and excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea, respectively.